• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    NanoVibronix Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Leadership Update

    8/14/25 4:06:29 PM ET
    $NAOV
    Industrial Specialties
    Health Care
    Get the next $NAOV alert in real time by email
    false 0001326706 0001326706 2025-08-11 2025-08-11 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the

    Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): August 11, 2025

     

    NanoVibronix, Inc.

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-36445   01-0801232

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

     

    969 Pruitt Ave

    Tyler, Texas

      77569
    (Address of principal executive offices)   (Zip Code)

     

    Registrant’s telephone number, including area code: (914) 233-3004

     

     
    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol   Name of each exchange on which registered
    Common Stock, par value $0.001 per share   NAOV   Nasdaq Capital Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     
     

     

    Item 4.01 Changes in Registrant’s Certifying Accountant.

     

    (a) Dismissal of Independent Registered Public Accounting Firm

     

    On August 12, 2025, the Audit Committee of the Board of Directors (the “Committee”) of NanoVibronix, Inc. (the “Company”) approved the dismissal of Zwick CPA PLLC (“Zwick”) as the Company’s independent registered public accounting firm, effective as of the same date.

     

    The reports of Zwick on the Company’s consolidated financial statements for the two most recent fiscal years, ended December 31, 2024, and December 31, 2023, did not contain an adverse opinion or a disclaimer of opinion, and was not qualified or modified as to uncertainty, audit scope, or accounting principles, except Zwick’s report on the consolidated financial statements of the Company as of and for the years ended December 31, 2024, and December 31, 2023, contained an explanatory paragraph stating there was substantial doubt about the Company’s ability to continue as a going concern.

     

    During the two most recent fiscal years, ended December 31, 2024, and December 31, 2023, and the subsequent interim period through August 12, 2025, there were no disagreements (as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions to Item 304 of Regulation S-K) with Zwick on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of Zwick, would have caused Zwick to make reference to the subject matter of the disagreements in connection with its reports on the Company’s consolidated financial statements for such years. Also during this time, there were no “reportable events,” as defined in Item 304(a)(1)(v) of Regulation S-K, except that, for the years ended December 31, 2024, and December 31, 2023, and for each of the quarters within the years ended December 31, 2024, and 2023, management identified deficiencies in the Company’s design and effectiveness of their internal control over financial reporting that were considered to be material weaknesses.

     

    The Company provided Zwick with a copy of the above disclosures and requested that Zwick furnish the Company with a letter addressed to the Securities and Exchange Commission stating whether or not it agrees with the statements made above. A copy of Zwick’s letter dated August 14, 2025, is attached as Exhibit 16.1.

     

    (b) Appointment of New Independent Registered Public Accounting Firm

     

    On August 13, 2025, the Committee engaged Kost Forer Gabbay & Kasierer, a member of Ernst & Young Global (“E&Y”) as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025, effective immediately. During the fiscal years ended December 31, 2024, and December 31, 2023, and the subsequent interim period through August 13, 2025, neither the Company nor anyone on its behalf has consulted with E&Y regarding (i) the application of accounting principles to any specified transaction, either completed or proposed, or the type of audit opinion that might be rendered on the Company’s financial statements, and neither a written report nor oral advice was provided to the Company that E&Y concluded was an important factor considered by the Company in reaching a decision as to any accounting, auditing, or financial reporting issue, or (ii) any matter that was either the subject of a “disagreement,” as defined in Item 304(a)(1)(iv) of Regulation S-K, or a “reportable event,” as defined in Item 304(a)(1)(v) of Regulation S-K.

     

     
     

     

    Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.

     

    On August 11, 2025 (the “Brown Effective Date”), the Company entered into an amended and restated employment agreement (the “Brown Employment Agreement”) with Stephen Brown, Chief Financial Officer of the Company, which such agreement amends, restates and those certain employment agreements dated September 20, 2024, January 1, 2022, and October 5, 2020. Pursuant to the terms of the Brown Employment Agreement, the Company shall pay Mr. Brown an annual salary of $300,000, less any applicable payroll deductions and tax withholdings (the “Base Salary”). The Brown Employment Agreement shall be at-will and will remain in effect unless terminated by either party in accordance with the terms of the Brown Employment Agreement. Either

     

    Either the Company or Mr. Brown may terminate Mr. Brown’s employment with the Company at any time upon 30 days written notice to the other party, subject to the terms of the Brown Employment Agreement. In the event of such termination, the Company shall pay Mr. Brown the Base Salary through the date of termination and other customary accrued and reimbursable expenses. Additionally, in the event the Company terminates Mr. Brown’s employment for Cause (as defined in the Brown Employment Agreement) or the Mr. Brown voluntarily resigns for any reason on or before the six-month anniversary of the Brown Effective Date, the Company shall have no further liability or obligation Mr. Brown under the Brown Employment Agreement other than any customary accrued and reimbursable expenses. In the event Mr. Brown’s employment is terminated by (x) the Company without Cause following the Brown Effective Date or (y) Mr. Brown due to a resignation for any reason following the six-month anniversary of the Brown Effective Date, subject to certain terms and conditions of the Brown Employment Agreement, the Company shall pay Mr. Brown severance pay in a total amount equal to $180,000.

     

    Additionally, pursuant to the Brown Employment Agreement, Mr. Brown may not own over an aggregate of 2% of the outstanding stock of any class of any corporation engaged in a business that directly competes with the business of the Company if such stock is listed on a national securities exchange in the United States.

     

    The Brown Employment Agreement also provides for certain customary covenants regarding non-solicitation, non-competition and confidentiality.

     

    The foregoing is only a summary of the material terms of the Brown Employment Agreement and does not purport to be complete. The foregoing summary is qualified in its entirety by reference to the complete text of the Brown Employment Agreement, which is attached hereto as Exhibit 10.1 and incorporated herein by reference.

     

    Item 9.01 Financial Statements and Exhibits.

     

    (d) Exhibits

     

    Exhibit No.

      Description
    10.1   Amended and Restated Employment Agreement, dated as of August 11, 2025, by and between NanoVibronix, Inc. and Stephen Brown
    16.1   Letter from Zwick CPA PLLC to the Securities and Exchange Commission dated August 14, 2025
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

     
     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      NanoVibronix, Inc.
         
    Date: August 14, 2025 By: /s/ Doron Besser, M.D.
      Name: Doron Besser, M.D.
      Title: Chief Executive Officer

     

     

     

    Get the next $NAOV alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NAOV

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NAOV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    NanoVibronix Announces Reverse Stock Split

    Common Stock Will Begin Trading on Split-Adjusted Basis on August 12, 2025 NanoVibronix, Inc. (NASDAQ:NAOV) ("NanoVibronix" or the "Company"), a medical technology company specializing in non-invasive therapeutic devices, today announced that it intends to effect a reverse stock split of its common stock, par value $0.001 per share (the "common stock") at a ratio of 1 post-split share for every 10 pre-split shares. The reverse stock split will become effective at 4:05 p.m. ET on Monday, August 11, 2025. The Company's common stock will continue to be traded on the Nasdaq Capital Market under the symbol NAOV and will begin trading on a split-adjusted basis when the market opens on Tuesday,

    8/8/25 9:00:00 AM ET
    $NAOV
    Industrial Specialties
    Health Care

    NanoVibronix Announces Financing of up to $50 Million Private Placement of Preferred Stock

    Upfront $8 Million in Gross Proceeds and potential $40 million in Gross Proceeds from Exercise of Additional Investment Rights NanoVibronix, Inc. (NASDAQ:NAOV) ("NanoVibronix" or the "Company"), a medical technology company specializing in therapeutic devices for enteral feeding, pain management and urological conditions, today announced it has entered into a definitive agreement with an institutional investor for the purchase and sale of 8,889 shares of Series H Convertible Preferred Stock (the "Preferred Stock") with a total stated value of $8,888,889. The Preferred Stock is convertible into shares of the Company's common stock, par value $0.001 per share (the "Common Stock"), at an ini

    7/18/25 9:00:00 AM ET
    $NAOV
    Industrial Specialties
    Health Care

    NanoVibronix's ENvue Medical Division Announces Agreement with New York Medical Center to Implement ENvue™ Navigation Systems for Enteral Feeding Tube Placement

    Dual-System Agreement Highlights Transition Towards Advanced Bedside Navigation NanoVibronix, Inc. (NASDAQ:NAOV) ("NanoVibronix" or the "Company"), a medical technology company specializing in non-invasive therapeutic devices, announced today that a regional acute care hospital in upstate New York has signed an agreement to acquire two ENvue™ Navigation Systems through its ENvue Medical division ("ENvue" or "ENvue Medical"). The systems, which are currently expected to be delivered in the third quarter of 2025, will support bedside placement of nasoenteric feeding tubes in adult patients. ENvue's electromagnetic technology provides clinicians with real-time visualization of tube directi

    6/24/25 8:00:00 AM ET
    $NAOV
    Industrial Specialties
    Health Care

    $NAOV
    SEC Filings

    View All

    SEC Form 10-Q filed by NanoVibronix Inc.

    10-Q - NanoVibronix, Inc. (0001326706) (Filer)

    8/19/25 5:12:59 PM ET
    $NAOV
    Industrial Specialties
    Health Care

    NanoVibronix Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Leadership Update

    8-K - NanoVibronix, Inc. (0001326706) (Filer)

    8/14/25 4:06:29 PM ET
    $NAOV
    Industrial Specialties
    Health Care

    SEC Form NT 10-Q filed by NanoVibronix Inc.

    NT 10-Q - NanoVibronix, Inc. (0001326706) (Filer)

    8/14/25 4:05:18 PM ET
    $NAOV
    Industrial Specialties
    Health Care

    $NAOV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Executive Officer Murphy Brian M

    4 - NanoVibronix, Inc. (0001326706) (Issuer)

    1/3/25 4:05:16 PM ET
    $NAOV
    Industrial Specialties
    Health Care

    SEC Form 4 filed by Director Mika Thomas

    4 - NanoVibronix, Inc. (0001326706) (Issuer)

    1/2/25 9:26:30 PM ET
    $NAOV
    Industrial Specialties
    Health Care

    SEC Form 4 filed by Chief Financial Officer Brown Stephen Russell

    4 - NanoVibronix, Inc. (0001326706) (Issuer)

    1/2/25 9:25:07 PM ET
    $NAOV
    Industrial Specialties
    Health Care

    $NAOV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by NanoVibronix Inc.

    SC 13G/A - NanoVibronix, Inc. (0001326706) (Subject)

    11/14/24 5:17:34 PM ET
    $NAOV
    Industrial Specialties
    Health Care

    SEC Form SC 13G filed by NanoVibronix Inc.

    SC 13G - NanoVibronix, Inc. (0001326706) (Subject)

    2/14/24 3:45:41 PM ET
    $NAOV
    Industrial Specialties
    Health Care

    SEC Form SC 13G/A filed

    SC 13G/A - NanoVibronix, Inc. (0001326706) (Subject)

    2/16/21 3:49:24 PM ET
    $NAOV
    Industrial Specialties
    Health Care

    $NAOV
    Financials

    Live finance-specific insights

    View All

    NanoVibronix Announces Distribution of Series F Preferred Stock to Holders of its Common Stock

    NanoVibronix, Inc. (NASDAQ:NAOV) ("Nano" or the "Company"), a medical device company utilizing the Company's proprietary and patented low intensity surface acoustic wave (SAW) technology, today announced that its Board of Directors declared a dividend of one one-thousandth of a share of newly designated Series F Preferred Stock, par value $0.001 per share, for each outstanding share of the Company's common stock held of record as of 5:00 p.m. Eastern Time on October 14, 2022. The shares of Series F Preferred Stock will be distributed to such recipients at 5:00 p.m. Eastern Time on October 17, 2022. The outstanding shares of Series F Preferred Stock will vote together with the outstanding sh

    9/14/22 9:25:00 AM ET
    $NAOV
    Industrial Specialties
    Health Care

    $NAOV
    Leadership Updates

    Live Leadership Updates

    View All

    NanoVibronix Announces CEO Transition

    NanoVibronix, Inc. (NASDAQ:NAOV) ("NanoVibronix" or the "Company"), a medical technology company specializing in therapeutic devices, today announced the retirement of Brian Murphy as Chief Executive Officer, effective immediately. The Company's Board of Directors has appointed Doron Besser, CEO of ENvue Medical Holdings, LLC ("ENvue"), a wholly-owned subsidiary of the Company, as NanoVibronix's new CEO, also effective immediately. Mr. Murphy will remain on the Company's Board of Directors as a director. His continued service will support governance continuity at the Board level. As previously announced, on February 14, 2025, the Company consummated and completed its acquisition of ENvue,

    6/4/25 8:38:00 AM ET
    $NAOV
    Industrial Specialties
    Health Care

    NanoVibronix Announces Results of Annual Meeting of Stockholders Held Today

    NanoVibronix, Inc. (NASDAQ:NAOV) (the "Company"), a medical device company utilizing the Company's proprietary and patented low intensity surface acoustic wave (SAW) technology, announced that the Company's 2022 annual meeting of stockholders (the "Annual Meeting") was held today virtually and broadcast live at www.virtualshareholdermeeting.com/NAOV2022. The following resolutions submitted for stockholder approval were adopted: Election of the eight director nominees (Aurora Cassirer, Christopher Fashek, Michael Ferguson, Martin Goldstein, M.D., Harold Jacob, M.D., Thomas Mika, Brian Murphy, and Maria Schroeder) to serve on the Company's board of directors (the "Board"), for a term of on

    12/15/22 4:05:00 PM ET
    $NAOV
    Industrial Specialties
    Health Care

    NanoVibronix Reports First Quarter 2022 Financial Results

    Expanded Distribution, Entry into New Geographic Markets and Regulatory Approvals Advancing Efforts Towards Full Commercialization NanoVibronix, Inc., (NASDAQ:NAOV), a medical device company utilizing the Company's proprietary and patented low intensity surface acoustic wave (SAW) technology, today reported its financial results for the quarter ended March 31, 2022. First Quarter 2022 Financial and Recent Business Highlights Revenue of $272,000, an increase of 164% compared to the prior year period Significant backlog of orders to be filled in Q2 Supply chain challenges are expected to abate moving into the second half of 2022 Submitted a 510(k) application to the U.S. Food and Dr

    5/17/22 8:30:00 AM ET
    $NAOV
    Industrial Specialties
    Health Care